nodes	percent_of_prediction	percent_of_DWPC	metapath
Nizatidine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0259	0.475	CbGbCtD
Nizatidine—ABCB1—Vincristine—lymphatic system cancer	0.0178	0.327	CbGbCtD
Nizatidine—Hyperuricaemia—Fludarabine—lymphatic system cancer	0.0167	0.0177	CcSEcCtD
Nizatidine—Blood uric acid increased—Fludarabine—lymphatic system cancer	0.0158	0.0167	CcSEcCtD
Nizatidine—Jaundice—Mechlorethamine—lymphatic system cancer	0.013	0.0138	CcSEcCtD
Nizatidine—Bronchospasm—Teniposide—lymphatic system cancer	0.0109	0.0115	CcSEcCtD
Nizatidine—ABCB1—Methotrexate—lymphatic system cancer	0.0108	0.198	CbGbCtD
Nizatidine—Hyperuricaemia—Vincristine—lymphatic system cancer	0.0102	0.0108	CcSEcCtD
Nizatidine—Hyperuricaemia—Mitoxantrone—lymphatic system cancer	0.00993	0.0105	CcSEcCtD
Nizatidine—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00974	0.0103	CcSEcCtD
Nizatidine—Blood uric acid increased—Vincristine—lymphatic system cancer	0.00963	0.0102	CcSEcCtD
Nizatidine—Sweating—Teniposide—lymphatic system cancer	0.00945	0.00999	CcSEcCtD
Nizatidine—Blood uric acid increased—Mitoxantrone—lymphatic system cancer	0.00938	0.00992	CcSEcCtD
Nizatidine—Gynaecomastia—Carmustine—lymphatic system cancer	0.00887	0.00938	CcSEcCtD
Nizatidine—Pneumonia—Fludarabine—lymphatic system cancer	0.00871	0.00921	CcSEcCtD
Nizatidine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00853	0.00902	CcSEcCtD
Nizatidine—Infection—Mechlorethamine—lymphatic system cancer	0.00847	0.00896	CcSEcCtD
Nizatidine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00835	0.00883	CcSEcCtD
Nizatidine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00813	0.0086	CcSEcCtD
Nizatidine—Sinusitis—Fludarabine—lymphatic system cancer	0.00813	0.00859	CcSEcCtD
Nizatidine—Pharyngitis—Fludarabine—lymphatic system cancer	0.00772	0.00816	CcSEcCtD
Nizatidine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00741	0.00784	CcSEcCtD
Nizatidine—Anaemia—Teniposide—lymphatic system cancer	0.00712	0.00753	CcSEcCtD
Nizatidine—Bronchospasm—Bleomycin—lymphatic system cancer	0.00701	0.00741	CcSEcCtD
Nizatidine—Chest pain—Teniposide—lymphatic system cancer	0.00656	0.00694	CcSEcCtD
Nizatidine—Pneumonia—Bleomycin—lymphatic system cancer	0.00639	0.00676	CcSEcCtD
Nizatidine—Confusional state—Teniposide—lymphatic system cancer	0.00634	0.0067	CcSEcCtD
Nizatidine—Anaemia—Fludarabine—lymphatic system cancer	0.00626	0.00662	CcSEcCtD
Nizatidine—Infection—Teniposide—lymphatic system cancer	0.00624	0.0066	CcSEcCtD
Nizatidine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00615	0.00651	CcSEcCtD
Nizatidine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00608	0.00643	CcSEcCtD
Nizatidine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00603	0.00638	CcSEcCtD
Nizatidine—Anorexia—Teniposide—lymphatic system cancer	0.00599	0.00634	CcSEcCtD
Nizatidine—Cough—Fludarabine—lymphatic system cancer	0.00591	0.00625	CcSEcCtD
Nizatidine—Convulsion—Fludarabine—lymphatic system cancer	0.00586	0.0062	CcSEcCtD
Nizatidine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00583	0.00617	CcSEcCtD
Nizatidine—Myalgia—Fludarabine—lymphatic system cancer	0.00576	0.0061	CcSEcCtD
Nizatidine—Pneumonia—Carmustine—lymphatic system cancer	0.00558	0.0059	CcSEcCtD
Nizatidine—Confusional state—Fludarabine—lymphatic system cancer	0.00557	0.00589	CcSEcCtD
Nizatidine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00552	0.00584	CcSEcCtD
Nizatidine—Infection—Fludarabine—lymphatic system cancer	0.00549	0.0058	CcSEcCtD
Nizatidine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00547	0.00578	CcSEcCtD
Nizatidine—Decreased appetite—Teniposide—lymphatic system cancer	0.00546	0.00578	CcSEcCtD
Nizatidine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00542	0.00573	CcSEcCtD
Nizatidine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00541	0.00572	CcSEcCtD
Nizatidine—Rash—Mechlorethamine—lymphatic system cancer	0.00538	0.00569	CcSEcCtD
Nizatidine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00537	0.00568	CcSEcCtD
Nizatidine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00534	0.00565	CcSEcCtD
Nizatidine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00532	0.00563	CcSEcCtD
Nizatidine—Pneumonia—Vincristine—lymphatic system cancer	0.00532	0.00563	CcSEcCtD
Nizatidine—Anorexia—Fludarabine—lymphatic system cancer	0.00527	0.00557	CcSEcCtD
Nizatidine—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00518	0.00548	CcSEcCtD
Nizatidine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00518	0.00548	CcSEcCtD
Nizatidine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00514	0.00544	CcSEcCtD
Nizatidine—Sweating—Vincristine—lymphatic system cancer	0.00507	0.00537	CcSEcCtD
Nizatidine—Nausea—Mechlorethamine—lymphatic system cancer	0.00506	0.00536	CcSEcCtD
Nizatidine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00503	0.00532	CcSEcCtD
Nizatidine—Jaundice—Mitoxantrone—lymphatic system cancer	0.00502	0.00531	CcSEcCtD
Nizatidine—Urticaria—Teniposide—lymphatic system cancer	0.00499	0.00528	CcSEcCtD
Nizatidine—Body temperature increased—Teniposide—lymphatic system cancer	0.00497	0.00526	CcSEcCtD
Nizatidine—Abdominal pain—Teniposide—lymphatic system cancer	0.00497	0.00526	CcSEcCtD
Nizatidine—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00495	0.00523	CcSEcCtD
Nizatidine—Sweating—Mitoxantrone—lymphatic system cancer	0.00494	0.00523	CcSEcCtD
Nizatidine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00486	0.00514	CcSEcCtD
Nizatidine—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00485	0.00513	CcSEcCtD
Nizatidine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00484	0.00511	CcSEcCtD
Nizatidine—Decreased appetite—Fludarabine—lymphatic system cancer	0.0048	0.00508	CcSEcCtD
Nizatidine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00477	0.00504	CcSEcCtD
Nizatidine—Constipation—Fludarabine—lymphatic system cancer	0.00472	0.005	CcSEcCtD
Nizatidine—Pain—Fludarabine—lymphatic system cancer	0.00472	0.005	CcSEcCtD
Nizatidine—Vasculitis—Methotrexate—lymphatic system cancer	0.0047	0.00497	CcSEcCtD
Nizatidine—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.00467	0.00494	CcSEcCtD
Nizatidine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00464	0.00491	CcSEcCtD
Nizatidine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00463	0.00489	CcSEcCtD
Nizatidine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00459	0.00486	CcSEcCtD
Nizatidine—Anaemia—Bleomycin—lymphatic system cancer	0.00459	0.00485	CcSEcCtD
Nizatidine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00455	0.00481	CcSEcCtD
Nizatidine—Asthenia—Teniposide—lymphatic system cancer	0.00451	0.00477	CcSEcCtD
Nizatidine—Pruritus—Teniposide—lymphatic system cancer	0.00445	0.0047	CcSEcCtD
Nizatidine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00437	0.00462	CcSEcCtD
Nizatidine—Cough—Bleomycin—lymphatic system cancer	0.00433	0.00458	CcSEcCtD
Nizatidine—Diarrhoea—Teniposide—lymphatic system cancer	0.0043	0.00455	CcSEcCtD
Nizatidine—Chest pain—Bleomycin—lymphatic system cancer	0.00423	0.00447	CcSEcCtD
Nizatidine—Myalgia—Bleomycin—lymphatic system cancer	0.00423	0.00447	CcSEcCtD
Nizatidine—Back pain—Carmustine—lymphatic system cancer	0.00419	0.00443	CcSEcCtD
Nizatidine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00411	0.00434	CcSEcCtD
Nizatidine—Confusional state—Bleomycin—lymphatic system cancer	0.00408	0.00432	CcSEcCtD
Nizatidine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00405	0.00428	CcSEcCtD
Nizatidine—Infection—Bleomycin—lymphatic system cancer	0.00402	0.00426	CcSEcCtD
Nizatidine—Anaemia—Carmustine—lymphatic system cancer	0.004	0.00423	CcSEcCtD
Nizatidine—Back pain—Vincristine—lymphatic system cancer	0.004	0.00423	CcSEcCtD
Nizatidine—Vomiting—Teniposide—lymphatic system cancer	0.004	0.00423	CcSEcCtD
Nizatidine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00397	0.00419	CcSEcCtD
Nizatidine—Asthenia—Fludarabine—lymphatic system cancer	0.00396	0.00419	CcSEcCtD
Nizatidine—Rash—Teniposide—lymphatic system cancer	0.00396	0.00419	CcSEcCtD
Nizatidine—Dermatitis—Teniposide—lymphatic system cancer	0.00396	0.00419	CcSEcCtD
Nizatidine—Headache—Teniposide—lymphatic system cancer	0.00394	0.00416	CcSEcCtD
Nizatidine—Pruritus—Fludarabine—lymphatic system cancer	0.00391	0.00413	CcSEcCtD
Nizatidine—Back pain—Mitoxantrone—lymphatic system cancer	0.0039	0.00412	CcSEcCtD
Nizatidine—Anorexia—Bleomycin—lymphatic system cancer	0.00386	0.00408	CcSEcCtD
Nizatidine—Anaemia—Vincristine—lymphatic system cancer	0.00382	0.00404	CcSEcCtD
Nizatidine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00378	0.004	CcSEcCtD
Nizatidine—Convulsion—Carmustine—lymphatic system cancer	0.00375	0.00397	CcSEcCtD
Nizatidine—Nausea—Teniposide—lymphatic system cancer	0.00373	0.00395	CcSEcCtD
Nizatidine—Anaemia—Mitoxantrone—lymphatic system cancer	0.00372	0.00394	CcSEcCtD
Nizatidine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00369	0.0039	CcSEcCtD
Nizatidine—Chest pain—Carmustine—lymphatic system cancer	0.00369	0.0039	CcSEcCtD
Nizatidine—Myalgia—Carmustine—lymphatic system cancer	0.00369	0.0039	CcSEcCtD
Nizatidine—Anxiety—Carmustine—lymphatic system cancer	0.00368	0.00389	CcSEcCtD
Nizatidine—Convulsion—Vincristine—lymphatic system cancer	0.00358	0.00379	CcSEcCtD
Nizatidine—Confusional state—Carmustine—lymphatic system cancer	0.00357	0.00377	CcSEcCtD
Nizatidine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00353	0.00373	CcSEcCtD
Nizatidine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00352	0.00372	CcSEcCtD
Nizatidine—Myalgia—Vincristine—lymphatic system cancer	0.00352	0.00372	CcSEcCtD
Nizatidine—Cough—Mitoxantrone—lymphatic system cancer	0.00351	0.00372	CcSEcCtD
Nizatidine—Infection—Carmustine—lymphatic system cancer	0.00351	0.00372	CcSEcCtD
Nizatidine—Vomiting—Fludarabine—lymphatic system cancer	0.00351	0.00372	CcSEcCtD
Nizatidine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00349	0.00369	CcSEcCtD
Nizatidine—Rash—Fludarabine—lymphatic system cancer	0.00348	0.00368	CcSEcCtD
Nizatidine—Dermatitis—Fludarabine—lymphatic system cancer	0.00348	0.00368	CcSEcCtD
Nizatidine—Pain—Bleomycin—lymphatic system cancer	0.00346	0.00366	CcSEcCtD
Nizatidine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00346	0.00366	CcSEcCtD
Nizatidine—Headache—Fludarabine—lymphatic system cancer	0.00346	0.00366	CcSEcCtD
Nizatidine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00343	0.00363	CcSEcCtD
Nizatidine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00343	0.00363	CcSEcCtD
Nizatidine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00342	0.00361	CcSEcCtD
Nizatidine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00338	0.00357	CcSEcCtD
Nizatidine—Anorexia—Carmustine—lymphatic system cancer	0.00337	0.00356	CcSEcCtD
Nizatidine—Infection—Vincristine—lymphatic system cancer	0.00335	0.00355	CcSEcCtD
Nizatidine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00334	0.00353	CcSEcCtD
Nizatidine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00331	0.00351	CcSEcCtD
Nizatidine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0033	0.0035	CcSEcCtD
Nizatidine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00329	0.00348	CcSEcCtD
Nizatidine—Nausea—Fludarabine—lymphatic system cancer	0.00328	0.00347	CcSEcCtD
Nizatidine—Infection—Mitoxantrone—lymphatic system cancer	0.00327	0.00345	CcSEcCtD
Nizatidine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00326	0.00345	CcSEcCtD
Nizatidine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00322	0.00341	CcSEcCtD
Nizatidine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00322	0.0034	CcSEcCtD
Nizatidine—Urticaria—Bleomycin—lymphatic system cancer	0.00322	0.0034	CcSEcCtD
Nizatidine—Anorexia—Vincristine—lymphatic system cancer	0.00322	0.0034	CcSEcCtD
Nizatidine—Body temperature increased—Bleomycin—lymphatic system cancer	0.0032	0.00339	CcSEcCtD
Nizatidine—Insomnia—Carmustine—lymphatic system cancer	0.0032	0.00338	CcSEcCtD
Nizatidine—Irritability—Methotrexate—lymphatic system cancer	0.00318	0.00336	CcSEcCtD
Nizatidine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00318	0.00336	CcSEcCtD
Nizatidine—Somnolence—Carmustine—lymphatic system cancer	0.00314	0.00332	CcSEcCtD
Nizatidine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00313	0.00331	CcSEcCtD
Nizatidine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00308	0.00325	CcSEcCtD
Nizatidine—Decreased appetite—Carmustine—lymphatic system cancer	0.00307	0.00325	CcSEcCtD
Nizatidine—Insomnia—Vincristine—lymphatic system cancer	0.00305	0.00323	CcSEcCtD
Nizatidine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00305	0.00323	CcSEcCtD
Nizatidine—Constipation—Carmustine—lymphatic system cancer	0.00302	0.0032	CcSEcCtD
Nizatidine—Pain—Carmustine—lymphatic system cancer	0.00302	0.0032	CcSEcCtD
Nizatidine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00299	0.00317	CcSEcCtD
Nizatidine—Decreased appetite—Vincristine—lymphatic system cancer	0.00293	0.0031	CcSEcCtD
Nizatidine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00292	0.00309	CcSEcCtD
Nizatidine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00291	0.00308	CcSEcCtD
Nizatidine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00291	0.00308	CcSEcCtD
Nizatidine—Asthenia—Bleomycin—lymphatic system cancer	0.00291	0.00307	CcSEcCtD
Nizatidine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00289	0.00306	CcSEcCtD
Nizatidine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00289	0.00306	CcSEcCtD
Nizatidine—Pain—Vincristine—lymphatic system cancer	0.00289	0.00305	CcSEcCtD
Nizatidine—Constipation—Vincristine—lymphatic system cancer	0.00289	0.00305	CcSEcCtD
Nizatidine—Pruritus—Bleomycin—lymphatic system cancer	0.00287	0.00303	CcSEcCtD
Nizatidine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00286	0.00302	CcSEcCtD
Nizatidine—Eosinophilia—Methotrexate—lymphatic system cancer	0.00285	0.00302	CcSEcCtD
Nizatidine—Constipation—Mitoxantrone—lymphatic system cancer	0.00281	0.00297	CcSEcCtD
Nizatidine—Pain—Mitoxantrone—lymphatic system cancer	0.00281	0.00297	CcSEcCtD
Nizatidine—Abdominal pain—Carmustine—lymphatic system cancer	0.0028	0.00296	CcSEcCtD
Nizatidine—Body temperature increased—Carmustine—lymphatic system cancer	0.0028	0.00296	CcSEcCtD
Nizatidine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00276	0.00292	CcSEcCtD
Nizatidine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00271	0.00286	CcSEcCtD
Nizatidine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00269	0.00284	CcSEcCtD
Nizatidine—Abdominal pain—Vincristine—lymphatic system cancer	0.00267	0.00282	CcSEcCtD
Nizatidine—Body temperature increased—Vincristine—lymphatic system cancer	0.00267	0.00282	CcSEcCtD
Nizatidine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00265	0.00281	CcSEcCtD
Nizatidine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00261	0.00276	CcSEcCtD
Nizatidine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0026	0.00275	CcSEcCtD
Nizatidine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.0026	0.00275	CcSEcCtD
Nizatidine—Pneumonia—Methotrexate—lymphatic system cancer	0.00258	0.00273	CcSEcCtD
Nizatidine—Vomiting—Bleomycin—lymphatic system cancer	0.00258	0.00272	CcSEcCtD
Nizatidine—Rash—Bleomycin—lymphatic system cancer	0.00255	0.0027	CcSEcCtD
Nizatidine—Dermatitis—Bleomycin—lymphatic system cancer	0.00255	0.0027	CcSEcCtD
Nizatidine—Asthenia—Carmustine—lymphatic system cancer	0.00254	0.00268	CcSEcCtD
Nizatidine—Sweating—Methotrexate—lymphatic system cancer	0.00246	0.0026	CcSEcCtD
Nizatidine—Asthenia—Vincristine—lymphatic system cancer	0.00242	0.00256	CcSEcCtD
Nizatidine—Diarrhoea—Carmustine—lymphatic system cancer	0.00242	0.00256	CcSEcCtD
Nizatidine—Nausea—Bleomycin—lymphatic system cancer	0.00241	0.00254	CcSEcCtD
Nizatidine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00236	0.00249	CcSEcCtD
Nizatidine—Dizziness—Carmustine—lymphatic system cancer	0.00234	0.00247	CcSEcCtD
Nizatidine—Diarrhoea—Vincristine—lymphatic system cancer	0.00231	0.00244	CcSEcCtD
Nizatidine—Hepatitis—Methotrexate—lymphatic system cancer	0.00231	0.00244	CcSEcCtD
Nizatidine—Pharyngitis—Methotrexate—lymphatic system cancer	0.00229	0.00242	CcSEcCtD
Nizatidine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00225	0.00238	CcSEcCtD
Nizatidine—Vomiting—Carmustine—lymphatic system cancer	0.00225	0.00238	CcSEcCtD
Nizatidine—Dizziness—Vincristine—lymphatic system cancer	0.00223	0.00236	CcSEcCtD
Nizatidine—Rash—Carmustine—lymphatic system cancer	0.00223	0.00236	CcSEcCtD
Nizatidine—Dermatitis—Carmustine—lymphatic system cancer	0.00223	0.00236	CcSEcCtD
Nizatidine—Headache—Carmustine—lymphatic system cancer	0.00221	0.00234	CcSEcCtD
Nizatidine—Vomiting—Vincristine—lymphatic system cancer	0.00215	0.00227	CcSEcCtD
Nizatidine—Rash—Vincristine—lymphatic system cancer	0.00213	0.00225	CcSEcCtD
Nizatidine—Dermatitis—Vincristine—lymphatic system cancer	0.00213	0.00225	CcSEcCtD
Nizatidine—Headache—Vincristine—lymphatic system cancer	0.00211	0.00224	CcSEcCtD
Nizatidine—Nausea—Carmustine—lymphatic system cancer	0.0021	0.00222	CcSEcCtD
Nizatidine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00209	0.00221	CcSEcCtD
Nizatidine—Rash—Mitoxantrone—lymphatic system cancer	0.00207	0.00219	CcSEcCtD
Nizatidine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00207	0.00219	CcSEcCtD
Nizatidine—Headache—Mitoxantrone—lymphatic system cancer	0.00206	0.00218	CcSEcCtD
Nizatidine—Nausea—Vincristine—lymphatic system cancer	0.002	0.00212	CcSEcCtD
Nizatidine—Nausea—Mitoxantrone—lymphatic system cancer	0.00195	0.00206	CcSEcCtD
Nizatidine—Back pain—Methotrexate—lymphatic system cancer	0.00194	0.00205	CcSEcCtD
Nizatidine—Anaemia—Methotrexate—lymphatic system cancer	0.00185	0.00196	CcSEcCtD
Nizatidine—Cough—Methotrexate—lymphatic system cancer	0.00175	0.00185	CcSEcCtD
Nizatidine—Convulsion—Methotrexate—lymphatic system cancer	0.00174	0.00184	CcSEcCtD
Nizatidine—Chest pain—Methotrexate—lymphatic system cancer	0.00171	0.00181	CcSEcCtD
Nizatidine—Myalgia—Methotrexate—lymphatic system cancer	0.00171	0.00181	CcSEcCtD
Nizatidine—Confusional state—Methotrexate—lymphatic system cancer	0.00165	0.00175	CcSEcCtD
Nizatidine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00164	0.00173	CcSEcCtD
Nizatidine—Infection—Methotrexate—lymphatic system cancer	0.00163	0.00172	CcSEcCtD
Nizatidine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.0016	0.0017	CcSEcCtD
Nizatidine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00158	0.00167	CcSEcCtD
Nizatidine—Anorexia—Methotrexate—lymphatic system cancer	0.00156	0.00165	CcSEcCtD
Nizatidine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00149	0.00158	CcSEcCtD
Nizatidine—Insomnia—Methotrexate—lymphatic system cancer	0.00148	0.00157	CcSEcCtD
Nizatidine—Somnolence—Methotrexate—lymphatic system cancer	0.00146	0.00154	CcSEcCtD
Nizatidine—Dyspepsia—Methotrexate—lymphatic system cancer	0.00144	0.00152	CcSEcCtD
Nizatidine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00142	0.00151	CcSEcCtD
Nizatidine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00141	0.0015	CcSEcCtD
Nizatidine—Pain—Methotrexate—lymphatic system cancer	0.0014	0.00148	CcSEcCtD
Nizatidine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00135	0.00143	CcSEcCtD
Nizatidine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00134	0.00142	CcSEcCtD
Nizatidine—Urticaria—Methotrexate—lymphatic system cancer	0.0013	0.00138	CcSEcCtD
Nizatidine—Abdominal pain—Methotrexate—lymphatic system cancer	0.00129	0.00137	CcSEcCtD
Nizatidine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00129	0.00137	CcSEcCtD
Nizatidine—Asthenia—Methotrexate—lymphatic system cancer	0.00118	0.00124	CcSEcCtD
Nizatidine—Pruritus—Methotrexate—lymphatic system cancer	0.00116	0.00123	CcSEcCtD
Nizatidine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00112	0.00119	CcSEcCtD
Nizatidine—Dizziness—Methotrexate—lymphatic system cancer	0.00108	0.00115	CcSEcCtD
Nizatidine—Vomiting—Methotrexate—lymphatic system cancer	0.00104	0.0011	CcSEcCtD
Nizatidine—Rash—Methotrexate—lymphatic system cancer	0.00103	0.00109	CcSEcCtD
Nizatidine—Dermatitis—Methotrexate—lymphatic system cancer	0.00103	0.00109	CcSEcCtD
Nizatidine—Headache—Methotrexate—lymphatic system cancer	0.00103	0.00109	CcSEcCtD
Nizatidine—Nausea—Methotrexate—lymphatic system cancer	0.000973	0.00103	CcSEcCtD
